U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H11NO3
Molecular Weight 121.135
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TROMETHAMINE

SMILES

NC(CO)(CO)CO

InChI

InChIKey=LENZDBCJOHFCAS-UHFFFAOYSA-N
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2

HIDE SMILES / InChI

Molecular Formula C4H11NO3
Molecular Weight 121.135
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can be used to maintain the pH of body fluids. Tromethamine is indicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tham

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Metabolic Acidosis Associated with Cardiac Bypass Surgery: Initial dose: 500 mL (150 mEq) by slow intravenous infusion is considered adequate for most adults; up to 1000 mL may be required in severe cases Maximum dose: 500 mg/kg (227 mg/lb) over a period of not less than one hour Associated with Cardiac Arrest: If the chest is open: 2 to 6 g (62 to 185 mL of a 0.3 M solution) injected into the ventricular cavity If the chest is not open: 3.6 to 10.8 g (111 to 333 mL of a 0.3 M solution) injected into a larger peripheral vein if the chest is not open Comment: Do not inject into the cardiac muscle
Route of Administration: Intravenous
In Vitro Use Guide
25-100 mM Tris (Tromethamine) completely inhibits starch-synthase
Substance Class Chemical
Record UNII
023C2WHX2V
Record Status Validated (UNII)
Record Version